Manufacturer
Abbvie Deutschland GmbH and Co.KG
Contents
Olaparib
Indication
Monotherapy for maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Prior treatment must have included at least 2 courses of platinum-based regimens.
Instruction
Should be taken on an empty stomach: Take at least 1 hr after meal and refrain from eating for 2 hr after intake.
Drug interaction
Potentiated and prolongated myelosuppressive toxicity with other anticancer medicinal products. Closely monitor patients co-administered with vaccines or immunosuppressives. Decreased efficacy and mean Cmax by phenytoin, rifampicin, rifapentine, carbamazepine, nevirapine, phenobarb, St. John's wort. Increased mean Cmax by itraconazole, telithromycin, clarithromycin, PIs boosted with ritonavir or cobicistat, boceprevir, telaprevir, erythromycin, diltiazem, fluconazole, verapamil, grapefruit juice. Increased exposure by P-gp inhibitors. Clinical monitoring with concomitant CYP3A substrates or substrates with narrow therapeutic margin (eg, simvastatin, cisapride, cyclosporine, ergot alkaloids, fentanyl, pimozide, sirolimus, tacrolimus, quetiapine) and P-gp substrates. Reduced exposure to CYP1A2, 2B6 and 3A4 substrates. Increased exposure to OATP1B1, OCT1, OCT2, OAT3, MATE1 and MATE2K substrates.
Malaysia
